- Home
- APGE vs WGS Comparison
APGE vs WGS Comparison
Compare APGE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APGE | WGS |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | APGE | WGS |
|---|---|---|
| Price | $77.22 | $151.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $100.00 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 818.6K | 453.1K |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | N/A | $23.53 |
| P/E Ratio | ★ N/A | $2,102.42 |
| Revenue Growth | N/A | ★ 50.50 |
| 52 Week Low | $26.20 | $55.17 |
| 52 Week High | $78.12 | $170.87 |
Technical Indicators
Market Signals| Indicator | APGE | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 51.75 |
| Support Level | $74.48 | $156.17 |
| Resistance Level | $76.87 | $165.62 |
| Average True Range (ATR) | 3.37 | 7.38 |
| MACD | -0.06 | -1.79 |
| Stochastic Oscillator | 91.13 | 12.04 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.